EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Dextran vs. Crystalloid Priming Solution in Cardiac Surgery: A Randomized Trial on Acute Kidney Injury

Oskar Juvakka iD, Andreas Wallinder, Peter Hasse Møller-Sørensen, Klaus Matschke, Anders Jeppsson, Lukas Lannemyr

Acta Anaesthesiologica Scandinavica · 2026

DOI: 10.1111/aas.70139 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Anaesthesiologica Scandinavica, 2026. Verfasst von Oskar Juvakka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences at the Sahlgrenska Academy, University of Gothenburg, Sweden. Hauptthemen laut MEDLINE: Dextrans, Acute Kidney Injury, Crystalloid Solutions, Cardiac Surgical Procedures. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xvivo Perfusion.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute kidney injury (AKI) is a frequent complication following cardiac surgery involving cardiopulmonary bypass (CPB). This is partly attributable to crystalloid‐based priming solutions causing both hemolysis and loss of oncotic pressure with tissue edema. While colloids like albumin and starches have not shown clear benefits, pilot studies using dextran‐based priming reported improved oncotic pressure, reduced hemolysis, and lower levels of a renal injury marker, suggesting potential renal protective effects.

Objective

We hypothesized that a dextran‐based priming solution can reduce the incidence of postoperative AKI in high‐risk patients undergoing cardiac surgery with CPB.

Methods

In this randomized, controlled, double‐blinded, multicenter trial, adult patients with a calculated postoperative AKI risk of ≥ 50% were assigned to receive either a dextran or a crystalloid‐based CPB priming solution. The primary outcome was the incidence of AKI within 96 h postoperatively. Secondary outcomes included perioperative hemolysis, net fluid balance, and the need for postoperative renal replacement therapy.

Results

The trial was terminated early due to slow enrolment, with 101 of the planned 366 patients recruited. A total of 92 patients were included in the final analysis (43 in the dextran group, 49 in the control group). Postoperative AKI occurred in 81% and 53% of patients in the dextran and control groups, respectively (risk ratio 1.53, 95% confidence interval 1.15–2.06, p = 0.004). The dextran group demonstrated lower intraoperative hemolysis and a more favorable net fluid balance. Postoperative renal replacement therapy was required in 7% of the dextran group and 4% of the control group ( p = 0.66). No significant differences in adverse events were observed between the groups.

Conclusion

In high‐risk patients undergoing cardiac surgery with CPB, the use of a dextran‐based priming solution was associated with a significantly increased risk of postoperative AKI. Editorial Comment This randomized multicenter trial compared dextran to a crystalloid‐based priming solution during cardiopulmonary bypass in participants with elevated risk of acute kidney injury. While the trial had to be terminated due to slow enrolment after about a third of planned cases were included, acute kidney injury was significantly more common in the dextran group, contrary to the primary hypothesis of the study. The study highlights the complexity and logistical challenges of conducting randomized treatment protocols for cardiopulmonary bypass, but at the same time highlights the importance of conducting such studies. Trial Registration ClinicalTrials.gov identifier: NCT04293744

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DextransAcute Kidney InjuryCrystalloid SolutionsCardiac Surgical ProceduresPostoperative ComplicationsHumansMaleFemaleAgedDouble-Blind MethodMiddle AgedCardiopulmonary BypassIsotonic SolutionsHemolysisPlasma Substitutes

Substanzen

DextransCrystalloid SolutionsIsotonic SolutionsPlasma Substitutes

Autor:innen und Institutionen

  • Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences at the Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Department of Cardiothoracic Anaesthesia, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • XVIVO Perfusion, Gothenburg, Sweden.
  • Department of Cardiothoracic Anesthesiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Klinik für Herzchirurgie, Herzzentrum Dresden GmbH, Dresden, Germany.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

ORCID-Profile: Oskar Juvakka

Förderung

  • Xvivo Perfusion

Zitieren

APA

Juvakka, O., Wallinder, A., Møller-Sørensen, P. H., Matschke, K., Jeppsson, A., & Lannemyr, L. (2026). Dextran vs. Crystalloid Priming Solution in Cardiac Surgery: A Randomized Trial on Acute Kidney Injury. Acta Anaesthesiologica Scandinavica. https://doi.org/10.1111/aas.70139

Vancouver

Juvakka O, Wallinder A, Møller-Sørensen PH, Matschke K, Jeppsson A, Lannemyr L. Dextran vs. Crystalloid Priming Solution in Cardiac Surgery: A Randomized Trial on Acute Kidney Injury. Acta Anaesthesiologica Scandinavica. 2026. doi:10.1111/aas.70139

BibTeX
@article{Juvakka2026,
  author = {Juvakka, Oskar and Wallinder, Andreas and Møller-Sørensen, Peter Hasse and Matschke, Klaus and Jeppsson, Anders and Lannemyr, Lukas},
  title = {Dextran vs. Crystalloid Priming Solution in Cardiac Surgery: A Randomized Trial on Acute Kidney Injury},
  journal = {Acta Anaesthesiologica Scandinavica},
  year = {2026},
  doi = {10.1111/aas.70139}
}
Kostenlos starten →